GLIOBLASTOMA MULTIFORME

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This program provides gallium maltolate (GaM) to adults with glioblastoma that has come back or not responded to treatment, and who have run out of standard options. The goal is to offer a possible way to control the disease when nothing else is available. Participants must be 18…

This study tests whether adding the anti-viral drug valganciclovir to standard treatment can help people with glioblastoma, an aggressive brain cancer. The drug targets a common virus (CMV) found in most glioblastoma tumors, which may make the cancer more aggressive. About 220 ad…

This study tests a cancer vaccine called SurVaxM in 35 children whose brain tumors have come back or are hard to treat. The vaccine teaches the immune system to find and destroy tumor cells. The goal is to see if it is safe and helps control the disease.

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors more effectively. It involves 57 patients with recurrent glioblastoma, a fast-growing brain cancer. The goal is to find a safe dose and se…

This study aimed to test an experimental virus therapy, G207, given directly into the brain tumor along with a single dose of radiation for children whose high-grade glioma had come back after standard treatment. The goal was to see if this combination could help children live lo…

This early-phase trial tests a new gene therapy called Temferon for people with glioblastoma, a fast-growing brain cancer. The treatment uses the patient's own blood stem cells, modified to deliver interferon directly to the tumor. Up to 27 patients will receive a single injectio…

This study tests a drug called NanO2, given through an IV, to see if it can deliver more oxygen to brain tumors and make radiation therapy work better. About 87 adults with newly diagnosed glioblastoma will receive NanO2 or a placebo along with standard radiation and chemotherapy…

This early-stage study tested a drug called APX005M in 32 children whose brain tumors had come back or were hard to treat, including a type called DIPG. The goal was to find a safe dose and see how the body reacts. The drug works by helping the immune system attack the tumor cell…

This early-phase study tests whether adding high-dose vitamin C and an iron-based drug (ferumoxytol) to standard radiation and chemotherapy can help adults with a newly diagnosed aggressive brain tumor called glioblastoma. The main goal is to find a safe dose of the iron drug. Se…

This early-phase trial studies whether giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can help the immune system fight recurrent glioblastoma, an aggressive brain cancer. About 63 adults whose cancer returned after standard treatment will receive the dru…

This early-phase trial tests whether adding the drug AZD1390 to standard radiation therapy can help people with a fast-growing brain cancer called glioblastoma (grade 4 glioma). It includes both newly diagnosed and recurrent patients. The study first checks how much drug reaches …

This early-phase study tests whether a new type of immune cell therapy, made from the patient's own cells and modified to target a protein called CD70, is safe and feasible for adults with glioblastoma and children with high-grade gliomas. The therapy includes an extra modificati…

This study tests whether adding the experimental drug LAM561 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 144 adults aged 18 to 75 will receive either LAM561 or a placebo alongside their usual treatmen…

This study tests whether giving a higher radiation dose to a specific brain area (the subventricular zone) during standard treatment can delay tumor regrowth in people with newly diagnosed glioblastoma. About 60 participants will receive either the modified radiation plus standar…

This early-phase study tests a new drug called DSP-0390 in 39 adults whose high-grade glioma (a fast-growing brain tumor) has come back after prior treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be …

This early-phase study tests a genetically engineered virus (rQNestin34.5v.2) that targets and kills brain tumor cells. About 62 adults with recurrent malignant glioma will receive the virus injected directly into the tumor, sometimes with a drug called cyclophosphamide to boost …

This early study tests whether adding the drug S-Gboxin to standard radiation and chemotherapy can help people with glioblastoma or diffuse midline glioma, two aggressive brain cancers. About 10 participants whose tumors have returned or worsened will receive the combination. The…

This study tests a drug called ACP-196 (acalabrutinib) in adults whose glioblastoma brain tumor has come back after standard treatment. The goal is to see if the drug can shrink or control the tumor. About 24 participants will receive the drug, and their response will be measured…

This study tests whether adding high-dose vitamin C to the usual treatment (radiation and chemotherapy) can help adults with a newly diagnosed, aggressive brain tumor called glioblastoma live longer. About 90 participants will receive the vitamin C infusions alongside standard ca…

This study tests whether adding an experimental drug called BPM31510 (with vitamin K1) to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 50 adults will receive the combination, and researchers will track ho…

This study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib befo…

This study looks at how well the drug ribociclib gets into brain tumors in people with recurrent high-grade glioma or meningioma. About 48 participants will take the drug before their scheduled tumor removal surgery. The goal is to measure drug levels in the blood, spinal fluid, …

This early-stage trial is testing whether combining two immunotherapy drugs with a precise, high-dose radiation treatment is safe and might help control recurrent glioblastoma, a very aggressive brain cancer. The study involves about 16 patients whose cancer has returned after in…